Skip to content

Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?

Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02888041
Acronym
RE-DINO
Enrollment
160
Registered
2016-09-02
Start date
2016-12-31
Completion date
2022-04-23
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Ripening, Pregnancy

Keywords

Cervical ripening, Pregnancy, Vaginal Administration

Brief summary

According perinatal surveys, induction of labor is performed at more than 20% of pregnant women. According to a survey on the trigger practices in France, prostaglandins are widely used to initiate cervical ripening, usually by laying intravaginal dinoprostone (Propess®). The overall work-up rate due to the use of a single Propess® is 74.6% with 80% of vaginal deliveries. Currently, 25.4% of patients who was not put in work after 24 hours are triggered by oxytocin (Syntocinon®) or directly caesarean. The initial installation of intravaginal dinoprostone limits the use of oxytocin (Syntocinon®) or in lower doses. Using a second Propess® is carried out in several maternity hospitals, as reported by the survey on the cervical ripening practices in France. This second administration could be the solution to reduce the rate of caesarean in France which amounted to 20.8%.

Interventions

DRUGDinoprostone

In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.

In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient who is \>=18 years. * Term pregnancy \> 37 weeks * Induction of labor in progress, medically indicated * Patients who have had the establishment of a first Propess®, within 24 to 36 hours (before signing the consent) * Cephalic presentation * Unfavorable cervical conditions (Bishop score \<6) 1 hour prior to inclusion * Intact Membranes * Affiliated with a social security system * Having signed the consent form.

Exclusion criteria

* Multiple pregnancy * Uterus scar * Contraindications to epidural anesthesia * Contraindications to Propess®: recent history of pelvic inflammatory disease; hypersensitivity to prostaglandins Adverse effects appeared in the first Propess®: anaphylactic shock, disseminated intravascular coagulation (DIC). * Contraindications to Syntocinon: Hypersensitivity to oxytocin, cardiovascular disorders and severe toxemia of pregnancy. * Contraindications to vaginal delivery (placenta previa, previa obstacle ...) * Premature Rupture of Membranes (PROM) * Intra Uterine Growth Retardation (IUGR) \<3rd percentile * Macrosomia\> 97th percentile * Severe Impaired fetal heart rate * In Utero Fetal Death (IUFD) * Medical Termination of pregnancy or lethal fetal pathology * Patient under guardianship or trusteeship safeguard justice

Design outcomes

Primary

MeasureTime frameDescription
Rate of deliveries vaginallyAt deliveryThe rate of births vaginally in each arm

Secondary

MeasureTime frameDescription
Time of workdelivery timeTime in minutes between the start of work defined by the onset of regular uterine contractions and cervical dilation ≥3 cm and delivery.
Caesarean indicationsAt deliveryCaesarean indications
Proportion of instrumental deliveryAt deliveryThe proportion of instrumental delivery
Proportion of complications of delivery and various care.Day 1The proportion of complications of delivery and various care.
Proportion of complete uterine ruptureAt deliveryThe proportion of complete uterine rupture
Transfer in Intensive Care Unit10 DaysThe transfer in Intensive Care Unit
Failure of induction of laborAt deliveryThe failure of induction of labor correspond to cervical dilation remaining \<3cm despite 6 hours of Syntocinon (or 1 syringe) and regular uterine contractions and amniotomy. The success of the trigger is defined by regular uterine contractions and cervical dilatation ≥ 3 cm.
Hospital stay of mother10 DaysHospital stay of mother
Apgar score3 Min, 5 Min and 10 MinDetermination of Apgar score
Visual estimation of presence of amniotic fluid meconiumAt the birthVisual estimation of presence of meconium in amniotic fluid. Absence of meconium if transparent and presence if colored.
Proportion of transfer neonatal or newborn intensive care unitAt the birthThe proportion of transfer neonatal or newborn intensive care unit
Fetal / neonatal deathAt the birthFetal / neonatal death
Assessment of fetal acidosis by measuring of pH, lactates and base excessAt the birthAssessment of fetal acidosis by measuring of pH, lactates and base excess
Maternal death10 DaysMaternal death

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026